PCI Mandates Aadhaar-Based Attendance System For Staff

New Delhi:  The Pharmacy Council of India (PCI) has announced a phased implementation of the Aadhaar Enabled Biometric Attendance System (AEBAS) in all PCI-approved pharmacy institutions, starting from the 2025-2026 academic session. This system aims to monitor attendance for faculty and non-faculty staff. This circular was issuedon January 24, 2025.

The AEBAS will be rolled out in phases, with the first phase focusing on attendance monitoring for all staff.

Action Items for Institutions

All institutions must acquire STQC-certified biometric authentication devices by February 23, 2025.

Institutions need to share details of the installed devices with valid QR codes on the SIF Application (DigiPHARMed Portal) along with signed and sealed invoices.

Procurement must adhere to the STQC-certified device specifications outlined in Appendix D of the AEBAS Guidelines.

Wall-mounted devices are preferred for most employees. USB fingerprint scanners or IRIS scanners with Windows 7/8 desktops can be used for senior staff or specific sections. Alternatives like wall-mounted iris scan or face recognition devices can be used only if fingerprint authentication fails.

Institutions must purchase enough devices to guarantee daily attendance recording for all staff.

Institutions are responsible for procuring, installing, and configuring devices directly from vendors. They should ensure detailed terms and conditions for after-sales support.

A stable internet connection is crucial for the system’s functionality. Institutions are responsible for maintaining sufficient AEBAS devices with Wi-Fi or fiber optic internet connectivity. Consistent biometric data capture is essential, and the PCI will take action for gaps exceeding 3 working days without justification.

PCI Responsibilities

The PCI will not handle communication regarding device maintenance issues. Furthermore, the PCI will provide further instructions for implementing the attendance monitoring system in due course.

This notification emphasizes the importance of immediate action for pharmacy institutions. Strict compliance is mandatory. Institutions must prioritize acquiring the required devices, ensuring proper internet connectivity, and maintaining a smooth data capture process.

SOURCE : Legality Simplified

Related Posts

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

Pak-made illegal cosmetics recovered from Itwari shop

Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert